Different expression patterns and clinical significance of mAxl and sAxl in systemic lupus erythematosus

Lupus

Volumn 23, Issue 7, 2014, Pages 624-634

  Zhu, H ^a   Sun, X ^a   Zhu, L ^a   Hu, F ^a   Shi, L ^a   Fan, C ^a   Li, Z ^a   Su, Y ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Anti dsDNA antibodies; Apoptosis; Axl receptor tyrosine kinases; SLEDAI; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; DOUBLE STRANDED DNA ANTIBODY; GROWTH ARREST SPECIFIC PROTEIN 6; MEMBRANE AXL RECEPTOR TYROSINE KINASE; PROTEIN TYROSINE KINASE; SOLUBLE AXL RECEPTOR TYROSINE KINASE; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; ONCOPROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOREGULATION; MACROPHAGE; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; BIOSYNTHESIS; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ADULT; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84903629445     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314520839     Document Type: Article

References (27)

1. Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus- an update. Curr Opin Immunol 2012; 24: 651-657.
2. Gaipl US, Kuhn A, Sheriff A, et al. Clearance of apoptotic cells in human SLE. Curr Dir Autoimmun 2006; 9: 173-187.
3. Rönnblom L, Pascual V. The innate immune system in SLE: Type I interferons and dendritic cells. Lupus 2008; 17: 394-399.
4. Nagata S, Hanayama R, Kawane K. Autoimmunity and the clearance of dead cells. Cell 2010; 140: 619-630.
5. Gaipl US, Munoz LE, Grossmayer G, et al. Clearance deficiency and systemic lupus erythematosus. J Autoimmun 2007; 28: 114-121.
6. Muñoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010; 6: 280-289.
7. Rothlin CV, Lemke G. TAM receptor signaling and autoimmune disease. Curr Opin Immunol 2010; 22: 740-746.
8. Lemke G, Burstyn-Cohen TA. TAM receptors and the clearance of apoptotic cells. Ann N Y Acad Sci 2010; 1209: 23-29.
9. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007; 131: 1039-1041.
10. Sharif MN, Sosic D, Rothlin CV, et al. Twist mediates suppression of inflammation by type I IFNs and Axl. J Exp Med 2006; 203: 1891-1901.
11. Alciato F, Sainaghi PP, Sola D, Castello L, Avanzi GC. TNFalpha, IL-6, and IL-1 expression is inhibited by GAS6 in monocytes/ macrophages. J Leukoc Biol 2010; 87: 869-875.
12. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001; 293: 306-311.
13. Seitz HM, Camenisch TD, Lemke G, Earp HS, Matsushima GK. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J Immunol 2007; 178: 5635-5642.
14. O'Bryan JP, Fridell YW, Koski R, Varnum B, Liu ET. The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage. J Biol Chem 1995; 270: 551-557.
15. Ekman C, Jönsen A, Sturfelt G, Bengtsson AA, Dahlbäck B. Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2011; 50: 1064-1069.
16. Gheita TA, Bassyouni IH, Bassyouni RH. Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl in patients with systemic lupus erythematosus and Behçets disease. J Clin Immunol 2012; 32: 1279-1286.
17. Morizono K, Xie Y, Olafsen T, et al. The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry. Cell Host Microbe 2011; 9: 286-298.
18. Korshunov VA. Axl-dependent signaling: A clinical update. Clin Sci (Lond) 2012; 122: 361-368.
19. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-2686.
20. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
21. Su Y, Jia RL, Han L, Li ZG. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus. Clin Immunol 2007; 122: 115-120.
22. Fu SM, Deshmukh US, Gaskin F. Pathogenesis of systemic lupus erythematosus revisited 2011: End organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. J Autoimmun 2011; 37: 104-112.
23. Rönnblom L, Pascual V. The innate immune system in SLE: Type I interferons and dendritic cells. Lupus 2008; 17: 394-399.
24. Elkon KB, Wiedeman A. Type I IFN system in the development and manifestations of SLE. Curr Opin Rheumatol 2012; 24: 499-505.
25. Sather S, Kenyon KD, Lefkowitz JB, et al. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 2007; 109: 1026-1033.
26. Ekman C, Stenhoff J, Dahlbäck B. Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood. J Thromb Haemost 2010; 8: 838-844.
27. Suh CH, Hilliard B, Li S, Merrill JT, Cohen PL. TAM receptor ligands in lupus: Protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Res Ther 2010; 12: R146.